The molecular basis for the known intramembrane receptor/receptor interactions among G
protein-coupled receptors was postulated to be heteromerization based on receptor subtype …

Abstract Treatment of Parkinson's disease with L‐dopa therapy leads to long‐term
complications, including loss of drug efficacy and the onset of dyskinesia. Adenosine A2A …

Neurochemical and morphological evidence has shown that some neurotransmitters or
substances may be released from both synaptic and nonsynaptic sites for diffusion to target …

Objective: To evaluate the safety and efficacy of the adenosine A2A receptor antagonist
istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with …

In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …

Activation of adenosine A2A receptors (A2AR) has been shown to antagonize the function of
D2 dopaminergic regulation of striatal γ‐aminobutyric acid (GABA)‐ergic output and, thus …

Striatal neurones receive myriad of synaptic inputs originating from different sources.
Massive afferents from all areas of the cortex and the thalamus represent the most important …

The ventral striatum is included in brain circuits which connect brain areas classically
ascribed to the motor or to the limbic system. In fact, the ventral striatum is involved in the …

The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …

Adenosine A2A receptors are abundant in the caudate‐putamen and involved in the motor
control in several species. In MPTP‐treated monkeys, A2A receptor‐blockade with an …